Efficacy and safety of biotherapies in the treatment of systemic lupus erythematosus

Allergology and Immunology

This systematic review and meta-analysis aimed to evaluate the efficacy and safety of biotherapies in systemic lupus erythematosus (SLE). A total of 44 studies were included up to May 2021, covering 15 therapeutic classes, 25 biotherapies, and 16,889 patients. The primary endpoints were treatment response index, composite lupus assessment, and renal remission. Four types of biotherapies demonstrated clinical improvement in lupus:

Anti-interferons (anifrolumab, sifalimumab)
Anti-BAFF/BLyS and/or APRIL agents (belimumab, tabalumab, telitacicept)
An anti-CD20 monoclonal antibody (obinutuzumab)
An anti-IL12/IL23 monoclonal antibody (ustekinumab)

For some of these biotherapies, safety was not evaluated.

Source(s) :
Justin Chan et al. Safety and efficacy of biological agents in the treatment of Systemic Lupus Erythematosus (SLE). BMC Rheumatol. 2023 Oct 9;7(1):37. ;

Vaginal microbiome: a cause of miscarriage ?

By Ana Espino | Published on February 18, 2026 | 3 min read &...

“We’re going to get through this together”: emotional support in advanced childhood cancer

By Carolina Lima | Published on February 17, 2026 | 3 min read

What are our pimples really saying?

By Ana Espino | Published on February 17, 2026 | 3 min read